Analyst Price Targets — CERS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 1, 2026 11:44 am | — | BTIG | $4.00 | $2.03 | TheFly | Cerus upgraded to Buy from Neutral at BTIG |
| October 17, 2024 7:25 am | Mathew Blackman | Stifel Nicolaus | $3.00 | $1.80 | StreetInsider | Cerus (CERS) PT Lowered to $3 at Stifel |
| May 3, 2024 6:57 am | Brandon Folkes | Cantor Fitzgerald | $4.00 | $1.76 | StreetInsider | Cerus (CERS) PT Raised to $4 at Cantor Fitzgerald |
| April 12, 2024 7:15 am | Bill Bonello | Craig-Hallum | $5.00 | $1.79 | StreetInsider | Craig-Hallum Starts Cerus (CERS) at Buy, 'The Risk-Reward Trade-off Is Compelling' |
Latest News for CERS
Cerus (CERS) is pivoting toward higher-value therapeutic products while reducing its research cost burden, aided by substantial government funding. Q2 2026 results signal an inflection point: product revenue grew 10%, operating expenses fell 7%, and adjusted EBITDA more than tripled year-over-year. Management raised full-year revenue guidance for the second time this year, now projecting $229–231 million, reflecting…
Assenagon Asset Management S.A. lessened its holdings in Cerus Corporation (NASDAQ: CERS) by 74.8% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 315,050 shares of the biotechnology company's stock after selling 936,043 shares during the quarter.
Cerus Corporation (CERS) Q2 2026 Earnings Call Transcript
Cerus NASDAQ: CERS reported second-quarter product revenue growth of 10% year over year and raised the low end of its 2026 product revenue outlook, citing demand for its INTERCEPT blood-safety products in North America and overseas.
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today financial results for the second quarter ended June 30, 2026, and provided a business update. “This quarter we made significant progress in expanding patient access to safer blood components around the globe,” said Vivek Jayaraman, Cerus' president and chief executive officer. “I'm particularly pleased with the performance of our…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CERS.
U.S. House Trading
No House trades found for CERS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.